About the Authors

Patrice Dubreuil

patrice.dubreuil@inserm.fr (PD); olivier.hermine@nck.aphp.fr (OH)

Affiliations INSERM, U891, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hematopoiesis and Mechanisms of Oncogenesis, Centre de référence des mastocytoses, Marseille, France, Institut Paoli-Calmettes, Marseille, France, Univ Méditerranée, Marseille, France, AB Science SA, Paris, France

Sébastien Letard

Affiliations INSERM, U891, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hematopoiesis and Mechanisms of Oncogenesis, Centre de référence des mastocytoses, Marseille, France, Institut Paoli-Calmettes, Marseille, France, Univ Méditerranée, Marseille, France, AB Science SA, Paris, France

Marco Ciufolini

Affiliations AB Science SA, Paris, France, University of British Columbia, Department of Chemistry, Vancouver, British Columbia, Canada

Laurent Gros

Affiliation AB Science SA, Paris, France

Martine Humbert

Affiliation AB Science SA, Paris, France

Nathalie Castéran

Affiliation AB Science SA, Paris, France

Laurence Borge

Affiliations INSERM, U891, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hematopoiesis and Mechanisms of Oncogenesis, Centre de référence des mastocytoses, Marseille, France, Institut Paoli-Calmettes, Marseille, France, Univ Méditerranée, Marseille, France

Bérengère Hajem

Affiliation AB Science SA, Paris, France

Anne Lermet

Affiliation AB Science SA, Paris, France

Wolfgang Sippl

Affiliation Institute of Pharmaceutical Chemistry, Martin-Luther-Universität, Halle, Wittenberg, Germany

Edwige Voisset

Affiliations INSERM, U891, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hematopoiesis and Mechanisms of Oncogenesis, Centre de référence des mastocytoses, Marseille, France, Institut Paoli-Calmettes, Marseille, France, Univ Méditerranée, Marseille, France

Michel Arock

Affiliation Laboratory of Oncology and Molecular Pharmacology, CNRS, UMR 8113, Ecole Normale Supérieure de Cachan, Cachan, France

Christian Auclair

Affiliations AB Science SA, Paris, France, Laboratory of Oncology and Molecular Pharmacology, CNRS, UMR 8113, Ecole Normale Supérieure de Cachan, Cachan, France

Phillip S. Leventhal

Affiliation AB Science SA, Paris, France

Colin D. Mansfield

Affiliation AB Science SA, Paris, France

Alain Moussy

Affiliation AB Science SA, Paris, France

Olivier Hermine

patrice.dubreuil@inserm.fr (PD); olivier.hermine@nck.aphp.fr (OH)

Affiliations AB Science SA, Paris, France, Service d'Hematologie, CNRS, UMR 8147, Centre de référence des mastocytoses, Université Paris V René Descartes, Hôpital Necker, Paris, France

Competing Interests

This study was financially supported by AB Science, S.A., Paris, France. AB Science is the proprietary holder of masitinib. Masitinib is under clinical development by AB Science. P.D., S.L., M.C., L.G., M.H., N.C., B.H., A.L., C.A., P.S.L., C.D.M. and A.M. are employees of the study sponsor, AB Science. M.C., M.A. and O.H. are scientific advisors to the study sponsor, AB Science. P.D., M.C., L.G., M.H., A.L., A.M. and O.H. are shareholders of the study sponsor, AB Science. M.C., A.L. and A.M. are applicants on numerous patents pertaining to masitinib.

Author Contributions

Conceived and designed the experiments: PD MC LG MH AL MA CA OH. Performed the experiments: PD SL MC LG MH NC LB BH AL WS EV MA CA. Analyzed the data: PD MC LG MH NC BH AL WS MA CA PL CM AM OH. Wrote the paper: PD LG PL CM AM OH.